Advertisement

Pharmacokinetic and Therapeutic Studies with Misonidazole and Desmethylmisonidazole in Man

  • Norman M. Bleehen
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 42)

Abstract

The role of hypoxic cell radiosensitisers in the management of cancer in patients has been the subject of several meetings (1,2) including the present one. This report concerns itself with some clinical studies carried out by the author and his colleagues at Cambridge, England, principally with misonidazole (Ro 07-0582 Roche Laboratories, N.S.C. 261037) and more recently with its O-demethylated metabolite, desmethylmisonidazole (Ro 05-9963, Roche Laboratories, N.S.C. 261036).

Keywords

Cyst Fluid Hypoxic Cell Pilonidal Sinus Cancer Clinical Trial Plasma Pharmacokinetic 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hypoxic Cell Sensitisers in Radiobiology and Radiotherapy. 8th L. H. Gray Conference, Cambridge 5th–9th Sept. 1977. Br. J. Cancer 38:Suppl. II (1978).Google Scholar
  2. 2.
    Combined Modality Cancer Treatment. Radiation Sensitiser and Protectors Meeting. Key Biscayne, Florida. Oct. 3rd–6th, 1979. Cancer Clinical Trials 3: in press (1980).Google Scholar
  3. 3.
    C. R. Wiltshire, P. Workman, J. V. Watson and N. M. Bleehen, Clinical Studies with Misonidazole. Br.J.Cancer 37:Suppl.III, Br.J.Cancer 37:Suppl.III, 286 (1978).Google Scholar
  4. 4.
    P. Workman, C. R. Wiltshire, P. N. Plowman and N. M. Bleehen, Monitoring Salivary Misonidazole in Man: A possible alternative to plasma monitoring. Br.J.Cancer 38: 709 (1978).PubMedCrossRefGoogle Scholar
  5. 5.
    P. Workman, N. M. Bleehen and C. R. Wiltshire, Phenytoin shortens the half-life of the hypoxic cell radiosensitiser misonidazole in man: Implications for possible reduced toxicity. Br.J.Cancer 41: 307 (1980).CrossRefGoogle Scholar
  6. 6.
    N. M. Bleehen, The Cambridge Glioma Trial of Misonidazole and Radiation Therapy with Associated Pharmacokinetic Studies. Cancer Clinical Trials 3:in press (1980).Google Scholar
  7. 7.
    G. E. Adams, I. R. Flockhart, C. E. Smithen, I. J. Stratford, P. Wardman and M. E. Watts, Electron affinie Sensitisation, VII: A correlation between structures, one-electron reduction potential and efficiencies of nitroimidazoles as hypoxic cell radiosensitisers. Radiat. Res. 67:9 (1976).Google Scholar
  8. 8.
    I. R. Flockhart, P. W. Sheldon, I. J. Stratford and M. J. Watts, A Metabolite of the 2-nitroimidazole Misonidazole with Radio- sensitising properties. Int. J. Radiat Biol. 34: 91 (1978).CrossRefGoogle Scholar
  9. 9.
    J. M. Brown, N. Y. Yu and P. Workman, Pharmacokinetic consider-ations in testing Hypoxic Cell Radiosensitisers in Mouse Tumours. Br. J. Cancer 39: 310 (1979).PubMedCrossRefGoogle Scholar
  10. 10.
    P. Workman, C. J. Little, T. R. Marten, A. D. Dale, R. J. Ruane, I. R. Flockhart and N. M. Bleehen, Estimation of the Hypoxic Cell Sensitiser Misonidazole and its 0-demethylated metabolite in biological materials by reversed-phase high performance liquid chromatography. J, Chromatoff. 145: 507 (1978).CrossRefGoogle Scholar
  11. 11.
    P. Workman, Effects of pretreatment with Phenobarbitone and Phenytoin on the Pharmacokinetics and Toxicity of Misonidazole in Mice. Br.J.Cancer 40: 335 (1979).PubMedCrossRefGoogle Scholar
  12. 12.
    S. Dische, M. I, Saunders, P. Anderson, R. C. Urtasun, K. H, Karcher, H. D. Kogelnik, N. H. Bleehen, T. L. Phillips, T. H. Wasserman, The Neurotoxicity of Misonidazole: pooling data from five centres. Br.J.Radiol. 51: 1023 (1978).CrossRefGoogle Scholar
  13. 13.
    T. H. Wasserman, T. L. Phillips, G. Van Raalte, R. Urtasun, J. Partington, D. Koziol, J. G. Schwade, D. Gangji and J. M. Strong, The Neurotoxicity of Misonidazole: potential modifying role of phenytoin sodium and dexamethasone. Br.J.Radiol. 53: 172 (1980).PubMedCrossRefGoogle Scholar
  14. 14.
    P. Workman, The Neurotoxicity of Misonidazole: potential modifying role of dexamethasone. Br.J.Radiol. 53: 736 (1980).PubMedCrossRefGoogle Scholar
  15. 15.
    D. Ash, M. R. Smith and R. Bugden, The distribution of Misonidazole in Human Tumours and Normal Tissues. Br.J.Cancer 39: 503–509, 1979.PubMedCrossRefGoogle Scholar
  16. 16.
    S. Dische, M. I. Saunders, M. E. Lee, G. E. Adams and I. R. Flockhart, Clinical Testing of the Radiosensitiser Ro 07-0582. Experience with multiple doses. Br.J.Cancer 35: 567 (1977).PubMedCrossRefGoogle Scholar
  17. 17.
    R. C. Urtasun, J. D. R. Miller, V. Frunchak, D. Koziol, P. R. Band, J. D. Chapman and M. L. Feldstein, Radiotherapy Pilot Trials with Sensitisers of Hypoxic Cells: Metronidazole in supratentorial glioblastomas. Br.J.Radiol. 50: 602 (1977).PubMedCrossRefGoogle Scholar
  18. 18.
    S. Hornsey and A. White, Isoeffect Curve for Radiation Myelopathy. Br.J.Radiol. 53: 168 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    A. J. Van der Kogel, Late Effects of Radiation on the Spinal Cord. Dose effect relationships and pathogenesis. T.N.0., Rijswijk, Holland (1979).Google Scholar
  20. 20.
    J. Denekamp, N. J. McNally and J.F. Fowler, Misonidazole in Fractionated Radiotherapy: Little and often? Br.J.Radiol.: in press.Google Scholar
  21. 21.
    J. F. Fowler, G. E. Adams and J. Denekamp, Radiosensitisers of Hypoxic Cells in Solid Tumours. Cancer Treat. Rev. 3: 227 (1976).PubMedCrossRefGoogle Scholar
  22. 22.
    J. M. Yuhas, Misonidazole Enhancement of Acute and Late Radiation Injury to Rat Spinal Cord. Br.J.Cancer 40: 161 (1979).PubMedCrossRefGoogle Scholar
  23. 23.
    R. A. S. White and P. Workman, Pharmacokinetic and Tumour- penetration Properties of the Hypoxic Cell Radiosensitiser Desmethylmisonidazole (Ro 05-9963) in Dogs. Br.J.Cancer 41: 268 (1980).PubMedCrossRefGoogle Scholar
  24. 24.
    M. I. S. Saunders, S. Dische, P. Anderson and I. R. Flockhart, The Neurotoxicity of Misonidazole and its relationship to dose, half-life and concentration in serum. Br.J.Cancer 37 (Suppl.III): 268 (1978).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Norman M. Bleehen
    • 1
  1. 1.University Department and Medical Research Council Unit of Clinical Oncology and RadiotherapeuticsCambridgeEngland

Personalised recommendations